Fig 4. Subgroup analysis according to the current categorization of eligible disease modifying therapies as “first line” and “second line” drug options for the treatment of relapsing-remitting multiple sclerosis.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.